Brief: Igc Commences Phase 2 Clinical Trials Evaluating Drug Candidate Igc-Ad1 For The Treatment Of Agitation In Dementia From Alzheimer’S Disease
01/12/2022 13:34
Dec 1 (Reuters) - India Globalization Capital Inc
IGC.A :
* IGC COMMENCES PHASE 2 CLINICAL TRIALS EVALUATING DRUG
CANDIDATE
IGC-AD1 FOR THE TREATMENT OF AGITATION IN DEMENTIA FROM
ALZHEIMER’S DISEASE
Source text for Eikon: ID:nBw3Kw8VSa
Further company coverage: IGC.A
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on IGC Pharma
See all newsFocus: Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassification
Cannabis stocks climb after Trump signs order to ease curbs on marijuana (updated)
Cannabis stocks rise ahead of potential Trump order to ease marijuana restrictions
Brief: IGC Pharma's Unit Enters Sale Of Assets Agreement For $2.7 Million - SEC Filing
Brief: IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment